Guia de dosagem injetável
5-Amino-1MQ
Protocolos de dose, frequência e ciclo do protocolo. Uso educacional.
Protocolos para 5-Amino-1MQ
| Objetivo terapêutico | Dose | Frequência |
|---|---|---|
| Phase I trial simulation / tolerance test | 2.5 – 5.0 mg | 1× daily (SC injection, morning) |
| Standard metabolic protocol (HED- derived) | 5.0 – 10.0 mg | 1× daily (SC injection, after 1-week tolerance) |
| Upper therapeutic range | 10.0 – 15.0 mg | 1× daily (SC, experienced users only) |
| Cycling protocol (conservative) | 5.0 – 10.0 mg | 5-day-on / 2-day-off or 4-week-on / 2-week-off |
NotaEVIDENCE BASE: Preclinical data: 20 mg/kg SC in mice (3× daily) showed efficacy without adverse effects. Allometric scaling (÷12.3): Human Equivalent Dose = 1.63 mg/kg = ~114 mg/ day. HOWEVER: Mouse studies used SC route with ~100% bioavailability. This protocol assumes SC/IM injection in humans (high bioavailability). Oral protocols use 50-150 mg due to lower bioavailability (~20-30%). Injectable doses should be proportionally lower. | ||
NotaRATIONALE FOR DOSING: Starting dose 2.5-5 mg = conservative Phase I approach (1/20th of | ||
Limite máximo diário
Maximum daily total ≤ 15 mg SC/IM — Based on allometric scaling with 5× safety margin · Maximum daily total ≤ 15 mg SC/IM — Based on allometric scaling with 5× safety margin
Evidência e monitoramento
- EVIDENCE BASE: Preclinical data: 20 mg/kg SC in mice (3× daily) showed efficacy without adverse effects. Allometric scaling (÷12.3): Human Equivalent Dose = 1.63 mg/kg = ~114 mg/ day. HOWEVER: Mouse studies used SC route with ~100% bioavailability. This protocol assumes SC/IM injection in humans (high bioavailability). Oral protocols use 50-150 mg due to lower bioavailability (~20-30%). Injectable doses should be proportionally lower. RATIONALE FOR DOSING: Starting dose 2.5-5 mg = conservative Phase I approach (1/20th of theoretical HED). Standard dose 5-10 mg = moderate safety margin (1/10th of HED). Maximum 15 mg = aggressive ceiling with 7.5× safety factor. The original 25-75 mg injectable protocol appears to confuse oral and injectable dosing. Community injectable reports of 1-5 mg may be overly conservative but align with cautious first-in-human principles. No published human PK/PD data exists as of 2026.
- MONITORING: Given NNMT's role in methylation and NAD+ metabolism, consider baseline and periodic monitoring: AST/ALT (liver function), homocysteine (methylation status), fasting lipids, fasting glucose. Discontinue if: elevated liver enzymes, severe GI symptoms, unexplained fatigue, or cardiovascular symptoms.
- RATIONALE FOR DOSING: Starting dose 2.5-5 mg = conservative Phase I approach (1/20th of theoretical HED). Standard dose 5-10 mg = moderate safety margin (1/10th of HED). Maximum 15 mg = aggressive ceiling with 7.5× safety factor. The original 25-75 mg injectable protocol appears to confuse oral and injectable dosing. Community injectable reports of 1-5 mg may be overly conservative but align with cautious first-in-human principles. No published human PK/PD data exists as of 2026.
Duração e objetivo
| Peptídeo | Duração do Protocolo | Objetivo do Ciclo |
|---|---|---|
| 5-amino-1mq | Máximo de 12 semanas ON, mínimo de 8 semanas OFF | O ciclo é preferível devido à limitada disponibilidade de dados a longo prazo e para prevenir adaptação das vias metabólicas. |
Uso educacional
Este guia é uma referência técnica destinada a fins educacionais. Não substitui avaliação, prescrição ou acompanhamento por profissional de saúde habilitado. As doses citadas seguem literatura e ensaios clínicos disponíveis, mas a resposta individual pode variar.
Calcular reconstituição